Mar 22, 2019 / 06:45PM GMT
Operator
Welcome to the Lexicon Pharmaceuticals Regulatory Update Call. (Operator Instructions) As a reminder, this call is being recorded today, March 22, 2019.
I will now turn the call over to Dr. Kimberly Lee, Head of Investor Relations and Corporate Strategy. Please go ahead.
Kimberly Lee - Lexicon Pharmaceuticals, Inc. - Head of IR & Corporate Strategy
Thank you, Dietra. Good afternoon, and welcome to Lexicon Pharmaceuticals regulatory update call in which we will discuss the FDA's issuance and the Complete Response Letter for sotagliflozin in type 1 diabetes.
Joining me on today's call are Lonnel Coats, Lexicon's President and Chief Executive Officer; Alex Santini, Executive Vice President and Chief Commercial Officer; Dr. Pablo Lapuerta, Executive Vice President and Chief Medical Officer; Dr. Praveen Tyle, Executive Vice President of Research and Development; and Jeff Wade, Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.
After our formal remarks, we will open the call up for Q&A.
Lexicon Pharmaceuticals Inc to Provide a Regulatory Update on Sotagliflozin Conference Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers